Condition
Unresectable Stage III Non-small Cell Lung Cancer
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (3)
Trial Status
Unknown2
Recruiting1
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07561983Phase 2Not Yet RecruitingPrimary
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
NCT07408635Phase 2RecruitingPrimary
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
NCT04670445Not ApplicableUnknown
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
NCT04111913Phase 2UnknownPrimary
A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Showing all 4 trials